UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 24, 2020

DELMAR PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Nevada	001-37823	99-0360497
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

12707 High Bluff Dr., Suite 200
San Diego, CA 92130
(Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: (858) 350-4364

Not Applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	**DMPI**	**The Nasdaq Capital Market**

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On June 10, 2020, DelMar Pharmaceuticals, Inc. (the "Company" or "DelMar") announced the entry into an Agreement and Plan of Merger and Reorganization between the Company, Adgero Acquisition Corp., a wholly-owned subsidiary of DelMar incorporated in the State of Delaware ("Merger Sub"), and Adgero Biopharmaceuticals Holdings, Inc., a Delaware corporation ("Adgero"), pursuant to which Merger Sub will merge with and into Adgero, with Adgero surviving the merger and becoming a direct, wholly-owned subsidiary of DelMar (the "Merger"). In connection with the Merger, the Company is using the investor presentation attached hereto as Exhibit 99.1 to describe the proposed Merger.

Forward-Looking Statements

This Current Report on Form 8-K and the presentation attached hereto as Exhibit 99.1 contain forward-looking statements based upon DelMar's and Adgero's current expectations. This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by terminology such as "may," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar words. These statements are only predictions. DelMar and Adgero have based these forward-looking statements largely on their then-current expectations and projections about future events, as well as the beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond each of DelMar's and Adgero's control, and actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors relating to the consummation of the Merger, including but not limited to: (i) risks associated with DelMar's and Adgero's ability to obtain the stockholder approval required to consummate the proposed Merger and the timing of the closing of the proposed Merger, including the risks that a condition to closing would not be satisfied within the expected timeframe or at all or that the closing of the proposed Merger will not occur; (ii) the outcome of any legal proceedings that may be instituted against the parties and others related to the Merger Agreement; (iii) the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Merger Agreement, (iv) unanticipated difficulties or expenditures relating to the proposed Merger, the response of business partners and competitors to the announcement of the proposed Merger, and/or potential difficulties in employee retention as a result of the announcement and pendency of the proposed Merger; (v) whether the combined business of Adgero and DelMar will be successful, and (vi) those risks detailed in DelMar's most recent Annual Report on Form 10-K, the registration statement on Form S-4 related to the proposed Merger with Adgero and subsequent reports filed with the SEC, as well as other documents that may be filed by DelMar from time to time with the SEC. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Neither DelMar nor Adgero can assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. The forward-looking statements made in this communication relate only to events as of the date on which the statements are made. Except as required by applicable law or regulation, DelMar and Adgero undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. Investors should not assume that any lack of update to a previously issued "forward-looking statement" constitutes a reaffirmation of that statement.

Additional Information and Where to Find It

This presentation is for informational purposes only and does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities or a solicitation of any vote or approval. This presentation relates to the proposed Merger of DelMar and Adgero. In connection with the proposed Merger, DelMar has filed a registration statement on Form S-4, which includes a document that serves as a prospectus and proxy statement of DelMar (the "proxy statement/prospectus"), and DelMar will file other documents regarding the proposed Merger transaction with the U.S. Securities and Exchange Commission (the "SEC"). No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY, WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT STOCKHOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING THE PROPOSED MERGER. A definitive proxy statement/prospectus will be sent to DelMar's stockholders. Investors and security holders will be able to obtain these documents (when available) free of charge from the SEC's website at www.sec.gov. The documents filed by DelMar with the SEC may also be obtained free of charge from DelMar by requesting them by mail at DelMar Pharmaceuticals, Inc., 12707 High Bluff Drive, Suite 200, San Diego, CA 92130.

Participants in the Solicitation

DelMar and its respective directors and executive officers and other members of management and employees and certain of their respective significant stockholders may be deemed to be participants in the solicitation of proxies from DelMar stockholders in respect of the proposed merger transaction. Information about DelMar's directors and executive officers is available in DelMar's proxy statement, filed June 2, 2020 for the 2020 Annual Meeting of Stockholders, DelMar's Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which was filed with the SEC on September 9, 2019 and DelMar's Current Report on Form 8-K filed on September 9, 2019. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the proxy solicitation and a description of their direct and indirect interests, by security holding or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed merger transaction when they become available. Investors should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the SEC and DelMar as indicated above.

No Offer or Solicitation

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Investor Presentation, dated June 2020

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DELMAR PHARMACEUTICALS, INC.

Date: June 24, 2020

By: /s/ *Scott Praill*
Name: Scott Praill
Title: Chief Financial Officer

Exhibit 99.1

Corporate Presentation of Company following acquisition of Adgero ("Kintara Therapeutics")

June 2020

Forward Looking Statements and Confidentiality

Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein or made in the course of the presentation are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the consummation of the merger, including DelMar's ability to obtain the stockholder approval required to consummate the proposed merger transaction and the timing of the closing of the proposed merger transaction, including the risks that a condition to closing would not be satisfied within the expected timeframe or at all or that the closing of the proposed merger transaction will not occur; the outcome of any legal proceedings that may be instituted against the parties and others related to the merger agreement; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger agreement, unanticipated difficulties or expenditures relating to the proposed merger transaction, the response of business partners and competitors to the announcement of the proposed merger transaction, and/or potential difficulties in employee retention as a result of the announcement and pendency of the proposed merger transaction; whether the combined business of Adgero and DelMar will be successful; the DelMar's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of DelMar's products and technology; the availability of substantial additional funding for DelMar to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, DelMar's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in DelMar Pharmaceuticals' filings with the SEC, including the registration statement on Form S-4 related to the proposed merger with Adgero, its Current Reports on Form 8-K, Form 10-Q's and most recent Form 10-K filing. DelMar Pharmaceuticals Inc. does not undertake to update these forward-looking statements made.

Persons receiving this presentation are hereby reminded of the confidentiality provisions and non-trading restrictions that they are subject to pursuant to a written Confidentiality Agreement that such persons have delivered for the benefit of DelMar Pharmaceuticals Inc. and Adgero Biopharmaceuticals Holdings, Inc.

Overview

DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) intends to acquire Adgero Biopharmaceuticals Holdings, Inc.

Publicly-traded Oncology-focused company with two late-stage therapeutics for multiple oncology indications with unmet medical needs

Both compounds developed through significant number of clinical studies resulting in well-established safety profiles and extensive historical data

Leveraging major prior investments in development of VAL-083 and REM-001

Compelling investment opportunity with significant near-term value generating milestones

Transaction Summary

DelMar to acquire Adgero and change its name to Kintara Therapeutics via an all share exchange transaction

Ownership upon completion of the merger:

- DelMar: 50.5%
- Adgero: 49.5%

Board composition: 7 total members

- 4 designated by DelMar
- 2 designated by Adgero
- 1 to be mutually selected

Unlocking Value Through Diversified and Reduced Risk Portfolio Strategy



Two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs

- Glioblastoma Multiforme (GBM): Adaptive design registration (Phase 2/3) trial through AGILE/GCAR – VAL-083
- Cutaneous Metastatic Breast Cancer (CMBC): Phase 3 protocol includes small confirmatory lead in trial (15 patients) with early assessment readout – REM-001

>$1B estimated market opportunity in GBM (>$800M[1]) and CMBC (~$500M[2])

Additional potential opportunities include indications with existing Orphan designations and/or approved INDs

- Ovarian Cancer (VAL-083); Basal Cell Carcinoma Nevus Syndrome (REM-001); Hemodialysis Grafts (REM-001)

Bolstered clinical development and domain expertise with the combination of DelMar and Adgero leadership

[1]GlobalData November 2018
[2]Charles River Associates April 2018

Phase 3-Ready Therapeutics

VAL-083 – First-in-class, small molecule, DNA-targeting agent
Lead Indication Glioblastoma multiforme (GBM)

REM-001 – Second-generation photodynamic therapy
Lead Indication Cutaneous Metastatic Breast Cancer (CMBC)

Both compounds risk reduced through:

- Significant previous investment in development
- Advanced manufacturing status
- Proven biological and tumor effecting activity
- Well-characterized molecules with significant safety databases
  - Approximately 1,100 patients in each safety database

Kintara Product Pipeline – Multiple Shots on Goal



ODD = Orphan Drug Designation FTD = Fast Track Designation STTR = NIH Small Business Technology Transfer Grant Filed



VAL-083 demonstrates activity in a wide range of cancer cell lines, including pediatric and adult GBM cell lines and GBM cancer stem cells.

VAL-083: GBM Opportunity

GBM provides major market opportunity due to high unmet medical need

- >$800M market opportunity growing to $1.4B in 2027[1]

Planned Registrational study through Global Coalition for Adaptive Research (GCAR) GBM AGILE Program

- FDA approved adaptive design study

MGMT methylation biomarker status screening optimizes patient selection and improves likelihood of success

[1]GlobalData November 2018

VAL-083: Clinical Data - Ongoing Phase 2 Studies

Newly Diagnosed Trial Arm* - Sun Yat-sen University Cancer Center

Median progression free survival (PFS)
[*historical comparator temozolomide at 6.9 months PFS*]

- **30 mg/m^2/day (n=25): 8.7 (CI 6.0-12.0) months;**
  (treatment dose for GCAR GBM AGILE Study)
- All patients (n=29): 8.7 (CI 6.4-11.2) months

Recurrent Trial Arm* - MD Anderson Cancer Center

Median Overall Survival (mOS)
[*historical comparator Lomustine at 7.2 months mOS*]

- **30 mg/m^2/day dose (n=27): 8.5 (CI 5.7-14.3) months**
  (treatment dose for GCAR GBM AGILE Study)
- All patients (n=72): 7.1 (CI 5.8-9.9) months

Enrollment Status*

- Newly diagnosed – enrollment complete at 29 patients
- Recurrent – 72 of planned 83 patients enrolled
- Adjuvant – 25 of planned 36 patients enrolled

**Open label Phase 2 studies in unmethylated patients; data from AACR Posters June 2020*

VAL-083: Expedited Development and Registration Pathway

Collaboration with the Global Coalition for Adaptive Research (GCAR)

Adaptive Global Innovative Learning Environment (AGILE) Study

- International effort in newly diagnosed and recurrent glioblastoma
- Master Protocol with three experimental arms versus a common control
- Primary endpoint: overall survival
- Adaptive design: learn (Stage 1) to confirm (Stage 2) in support of regulatory filing

Patients (150 to 200 maximum) stratified by three subtypes

- Newly-diagnosed methylated
- Newly-diagnosed unmethylated
- Recurrent

Capital flexibility with tranched clinical trial costs ($25M total)

- $15M for stage 1 (from private placement proceeds)
- $10M for stage 2 (to be provided from future financing sources)

GCAR/AGILE Advantages

Program led by KOLs with strong regulatory endorsement
- FDA letter of support

VAL-083 invited as additional treatment arm in study
- Bayer's Regorafenib already announced as part of study
- Exclusive to three treatment arms

Rapid study startup and patient enrollment
- 24 US sites currently enrolling patients
- Additional sites including expansion to EU, Canada and China anticipated in second half 2020
- Anticipate first patient enrolled five months from contract signature
- Results in significant potential savings in cost and time

Shared control group contains costs and improves robustness of study

GCAR's industry leading partners and vendors not typically available to smaller biotechs

Turnkey solution provides optimal registration pathway

GLOBAL COALITION FOR ADAPTIVE RESEARCH™

"Platform trials can accelerate the time from discovery in the laboratory to implementation in the clinic. ***GBM AGILE will raise the bar for all clinical trials****."*

Janet Woodcock, M.D.
Director of the Center for Drug Evaluation and Research
U.S. Food and Drug Administration

https://www.businesswire.com/news/home/20190619005230/en/Global-Coalition-Adaptive-Researchs-Innovative-Clinical-Trial

External Validation and Financial Support from NBTS and NFCR

Support in the form of $500,000 Loan

- National Brain Tumor Society (NBTS)
- National Foundation for Cancer Research (NFCR)

> We are supporting the inclusion of VAL-083 in GBM AGILE adaptive clinical trial platform as it is consistent with our mission to support research for, and ultimately enable delivery of, effective treatments to patients with brain tumors. We are particularly pleased to lend our support to VAL-083 given the significant unmet medical need that exists for patients with GBM.

National Brain Tumor Society

David Arons
Chief Executive Officer
National Brain Tumor Society

> We are dedicated to facilitating the development of therapies for all cancers, and are pleased to lend our support to VAL-083's participation in GBM AGILE. We are very hopeful that the knowledge established from VAL-083 in GBM AGILE can be insightful for other cancers – giving patients hope for treatments that are best suited for their care.

NATIONAL FOUNDATION FOR CANCER RESEARCH
Research for a Cure

Sujuan Ba
President & Chief Executive Officer
National Foundation for Cancer Research

REM001: CMBC Overview

Affects up to 40,000 patients in the U.S.[1]

CMBC is a highly morbid form of breast cancer characterized by unrelenting progression of multiple cutaneous tumor masses, especially following mastectomy

Clinical aspects

- Lesions may spread to chest wall, neck and back
- Continuous bleeding, infections and lesions are often malodorous
- Narcotics for pain control
- Some patients may become homebound, depressed and suicidal

Current therapies are limited

- Chemotherapy: generally non-responsive
- Radiation: dose limiting toxicities, lesions are often refractory to radiation

[1]Source (a): Saika et al, 2009; Kamaraju et al, 2016; Vano-Galvan et al, 2009; GlobalData Report on Metastatic Breast Cancer; Schoenlaub et al, 2001

REM-001: Advantages

Second Generation Photodynamic Therapy - Selective, Localized Outpatient Treatment

- Drug infused, accumulates in tumors
- Activated by simple red light

Robust mechanism of action

- Creates oxygen radicals
- Similar to radiation but avoids permanent damage

Favorable properties

- Clinical data indicates robust clinical safety and efficacy profile
- Limited photosensitivity
  (days vs. months with first generation photosensitizers)
- REM-001 selectively eliminates tumor tissue
- Modern, synthetic manufacturing process to meet current regulatory requirements
- Superior Key attributes (treatment depth, treatment timepoint, tumor selectivity)

REM-001: High Response Rates in CMBC



Extensive data from prior Phase 2/3 clinical trials

- 149 patients treated in these trials
- 80% complete response rate in evaluable lesions

Prior sponsor trial design issues

- Many patients forced to drop out if chemo restarted
- Used high dose, delayed post-treatment healing
- Did not use CRO to manage trial

Adgero optimized trial design

- Leverages high response rates
- Overcomes prior design issues
- Confirmatory trial design, reduced time/cost

REM-001 CMBC Phase 3 Preparation Complete

Identified pathway for smaller and faster trial design for higher likelihood of success

- Leveraging a lower dose through a confirmatory lead in to create a better overall opportunity

Prepared and filed a full Phase 3 protocol (including 15-patient confirmatory lead in)

Obtained positive FDA feedback regarding CMC amendment

- Manufacture of the regulatory starting material and active pharmaceutical ingredient completed
- Updated analytical methods required for CMC amendment, release, and stability testing of API
- Documentation package and engineering runs underway

REM-001: CMBC Overview and Market Opportunity

~$500M market opportunity[1]

Demonstrated 80% complete responses across four Phase 2/3 studies treating 149 CMBC patients

Optimized trial design focusing on and leveraging very high complete response rates (Phase 3 trial design does not preclude chemotherapy, radiation or surgery)

Phase 3 Trial Design

- Lead in portion of confirmatory study:
  ~$7M for manufacturing and 15-patient study
- Pivotal portion of the study:
  ~$20M to $30M for 100-patient study

[1]Charles River Associates April 2018

Additional Pipeline Opportunities



VAL-083 Follow-on Indications

- Ovarian Cancer
- Non-Small Cell Lung Cancer
- Other Solid Tumors

REM-001 Follow-on Indications

- Recurrent Basal Cell Carcinoma Nevus Syndrome
- Hemodialysis Arteriovenous (AV) Access
- Locally Advanced Basal Cell Carcinoma (laBCC)
- Other Cutaneous Metastatic Cancers
- Peripheral Lung Cancer

Barriers to Competition

VAL-083

GBM Orphan drug designation in US & EU
- Seven years market exclusivity after approval in US
- 10 years market exclusivity after approval in Europe

Sixteen patent families
- Claims to methods of use, dosing and administration, combinations, manufacturing, analytical methods, and mechanism of action

Thirteen US granted patents and twenty patents granted worldwide
- Expiry dates range from 2031 to 2038

Ovarian Orphan Drug Designation in US

REM-001

New Chemical Entity
- Five years data exclusivity after approval in US
- 8+2+1 Regime in Europe

Combination Product Regulatory Pathway
- REM-001 and Laser Device

Follow-on Indication Orphan Drug Designations in US
- Basal cell carcinoma nevus syndrome (BCCNS)
- Hemodialysis access grafts

Recent Achievements

Recent efforts by DelMar and Adgero set the stage for Kintara success

DelMar:

- Materially reduced cash burn
- Optimized VAL-083 dosing regimen across all patient populations
- Benefitted from accelerated enrollment in ongoing clinical trials
  - Expanded MDACC Phase 2 GBM study to include adjuvant stage patients
  - Completed enrollment in first-line unmethylated Phase 2 GBM study
- Selected to participate in groundbreaking GCAR GBM Agile adaptive design registration study
- Highly respected and prominent GBM Scientific Advisory Board

Adgero:

- Developed enhanced clinical development plan for REM-001
  - Leveraging lower dose through confirmatory lead in study
  - Improved trial design to optimize number of evaluable patients
- Filed Phase 3 protocol (including 15-patient confirmatory lead in) for CMBC
- Completed preparatory work to commence study
- Advanced CMC efforts including updated analytical methods

Near-Term Targeted Major Milestones[1]

Q4 2020

- VAL-083: First Patient Enrolled - GCAR GBM AGILE Registration Study
- VAL-083: Top Line Results - Phase 2 Newly Diagnosed GBM Study
- VAL-083: Top Line Results - Phase 2 Recurrent GBM Study

Q1 2021

- VAL-083: Top Line Results - Phase 2 Adjuvant GBM Study

Q2 2021

- REM-001: Confirmatory Trial Results - CMBC

Q1 2022

- VAL-083: Graduation from Stage 1 to Stage 2 - GCAR GBM AGILE Registration Study
- REM-001: Complete Phase 3 Enrollment - CMBC

[1]Pending sufficient financing in Q3, 2020

Senior Leadership Team

Saiid Zarrabian President and CEO	CEO of DelMar since November 2017; previously served as Chairman and Board Member of La Jolla Pharmaceutical Company, as President of the Protein Production Division of Intrexon Corporation, as CEO and member of the Board of Cyntellect, Inc, as President and COO of Senomyx, Inc., as COO of Pharmacopeia, Inc. and as President & COO of its MSI Division; has served on numerous private and public company boards, including at Immune Therapeutics, Inc., Exemplar Pharma, LLC, Ambit Biosciences Corporation, eMolecules, Inc., and Penwest Pharmaceuticals
Scott Praill CFO	CFO of DelMar since January 2013; previously consulted with multiple companies including DelMar; served as Director of Finance for Inflazyme Pharmaceuticals; worked at PricewaterhouseCoopers LLP for four years and completed a CPA in 1996
Dennis Brown CSO	DelMar founder, and Chief Scientific Officer since January 2013; served as a member of Board of Directors from February 2013 to April 2018; more than thirty years of successful drug discovery and development experience; B.A. in Biology and Chemistry, M.S. in Cell Biology, Ph.D. in Radiation and Cancer Biology
John Liatos Senior VP, Bus Dev	Interim CEO of Adgero since April 2018; prior to joining Adgero, was the co- founding partner at Aceras BioMedical, LLC., a healthcare-focused investment firm; responsible for business development, overall formation, and business strategy of Aceras and its portfolio companies
Greg Johnson Senior VP, Operations	28 years of international clinical research and drug development experience at contract research and biotech organizations; M.Sc. in Clinical Research; Project Management Professional (PMP) certification; Fellow of the Institute of Clinical Research (FICR)
Steve Rychnovsky VP, R&D	Co-founder and VP of Operations & Product Development of Adgero; experienced in all aspects of Adgero's photodynamic therapy technology; played a key role in development of Adgero's business strategy and implementation of plans for the development and commercialization of REM-001

GBM Scientific Advisory Board

Dr. Napoleone Ferrara
University of California, San Diego
World renowned scientist and Distinguished Professor of Pathology and a Distinguished Adjunct Professor of Ophthalmology and Pharmacology

Dr. John de Groot
MD Anderson Cancer Center
ad interim Chairman of the Department of Neuro-Oncology

Dr. Timothy Cloughesy
David Geffen School of Medicine (UCLA)
Professor of Neurology
UCLA Brain Research Institute and Jonsson Comprehensive Cancer Center
Member

Dr. David Reardon
Dana-Farber Cancer Institute
Clinical Director of the Center for Neuro-Oncology
Harvard Medical School
Professor of Medicine

Dr. Nicholas Butowski
UCSF Medical Center
Neuro-oncologist
Brain Tumor Center
Director of Translational Research in Neuro-Oncology and Researcher

CMBC Scientific Advisory Board

Thomas S. Mang, PhD
University at Buffalo (UB), School of Dental Medicine
Director of Research for Oral and Maxillofacial Surgery Department
Recognized PDT expert and prior clinical work with REM-001 Therapy

Stephen B. Solomon, MD
Memorial Sloan Kettering Hospital
Chairman, Interventional Radiology and Co-Director, Image-Guided Intervention
Specializes in image-guided interventions in cancer

Leonard A. Farber, MD
Weill Cornell Hospital
Radiation Oncologist
Specialties include adult radiation oncology for breast cancer patients
Experience in treating CMBC and recurrent basal cell carcinoma

Investment Highlights

Highly risk reduced, Late Stage Oncology focused company with:

- Two Phase 3 ready assets in indications with significant unmet medical need
- Phase 3 protocols ready for clinical trial initiation
- ~$500M to $800M market opportunity[1,2] for lead indications
- Multiple near-term value accretive clinical milestones
- Multiple US/EU Orphan Drug Designations as well as Fast Track for lead indication

Highly validated compounds enabled via significant prior investments:

- Validated efficacy in lead indications, including extensive clinical data
- Over 1,100 patient safety database for each molecule
- Late stage manufacturing status

[1]GlobalData November 2018
[2]Charles River Associates April 2018


DelMar
PHARMACEUTICALS
Clinical Operations
3475 Edison Way, Suite R
Menlo Park, CA 94025
USA
Corporate Headquarters
12707 High Bluff Dr., Suite 200
San Diego, CA 92130
USA
25


KINTARA
Therapeutics
Developing Advanced Oncology Therapies for Rare Unmet Medical Needs
Copyright © 2020 DelMar Pharmaceuticals Inc.

Additional Information and Where to Find It

This press release is for informational purposes only and does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities or a solicitation of any vote or approval. This press release relates to the proposed merger of DelMar and Adgero. In connection with the proposed merger, DelMar has filed a registration statement on Form S-4, which includes a document that serves as a prospectus and proxy statement of DelMar (the "proxy statement/prospectus"), and DelMar will file other documents regarding the proposed merger transaction with the U.S. Securities and Exchange Commission (the "SEC"). No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY, WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT STOCKHOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING THE PROPOSED MERGER. A definitive proxy statement/prospectus will be sent to DelMar's stockholders. Investors and security holders will be able to obtain these documents (when available) free of charge from the SEC's website at www.sec.gov. The documents filed by DelMar with the SEC may also be obtained free of charge from DelMar by requesting them by mail at DelMar Pharmaceuticals, Inc., 12707 High Bluff Drive, Suite 200, San Diego, CA 92130.

Participants in the Solicitation

DelMar and its respective directors and executive officers and other members of management and employees and certain of their respective significant stockholders may be deemed to be participants in the solicitation of proxies from DelMar stockholders in respect of the proposed merger transaction. Information about DelMar's directors and executive officers is available in DelMar's proxy statement, filed June 2, 2020 for the 2020 Annual Meeting of Stockholders, DelMar's Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which was filed with the SEC on September 9, 2019 and DelMar's Current Report on Form 8-K filed on September 9, 2019. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the proxy solicitation and a description of their direct and indirect interests, by security holding or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed merger transaction when they become available. Investors should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the SEC and DelMar as indicated above.

No Offer or Solicitation

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Appendix

Photodynamic Therapy Mechanisms of Action



Light
Energy Source

Photosensitizer
Catalyst to Activate, Absorb & Transfer Energy to Oxygen in Cells

Oxygen in Cell
Converted to ROS by Energy Transfer

Reactive O_2 (ROS)
Created by Energy Transfer

Diseased Cell Death
ROS Provides Mechanism of Action

PDT induces elimination of diseased cells by immune response, apoptosis, antiangiogenesis and necrosis

Necrosis Apoptosis



Enzymatic Digestion and Leakage of Cellular Contents

Phagocytosis of Apoptotic Cells and Fragments

Antiangiogenic / Anti-vascular



T - Cell Response



VAL-083 Mechanism of Action

VAL-083's unique cytotoxic mechanism circumvents MGMT-mediated chemoresistance and differentiates it from other therapies used in the treatment of GBM, including TMZ.

Mechanism of VAL-083 via crosslinks at N^7 of guanine



2 guanine bases on DNA *VAL-083* *VAL-083 – interstrand crosslink (ICL)*

Mechanism of temozolomide (TMZ) via alkylation at O^6 of guanine



temozolomide converts to active state (MTIC) at physiological pH *guanine base on DNA* *alkylation of O^6 guanine*

VAL-083's unique mechanism of action creates inter-strand DNA cross-links at the N^7 position of guanine, resulting in double-strand DNA breaks and cancer cell death via apoptosis